Farxiga (Dapagliflozin) in Children Under 12: Caregiver Administration Guidance

Is Farxiga Approved for Children Under 12?

Farxiga is not approved by the FDA for use in children under 12. The FDA-approved prescribing information specifies that dapagliflozin has not been established as safe or effective in pediatric patients under age 12 for any current indication. Caregivers who have been given or are considering this drug for a young child should stop and contact the prescribing physician immediately.

The FDA's 2023 updated label for dapagliflozin in chronic kidney disease (CKD) does not extend to patients under 12. For type 2 diabetes, the DERIVE trial (NCT02725593, N=314) evaluated dapagliflozin 5 mg and 10 mg in patients aged 10 to 17 years, forming part of the regulatory basis for a limited adolescent indication. Children under 10 were excluded entirely from that trial. [1]

What the FDA Label Actually Says

The current FDA prescribing information states that safety and effectiveness of dapagliflozin in pediatric patients under 12 years of age have not been established for the CKD indication, and under 10 years for the type 2 diabetes indication. [2] No dose has been validated, no pharmacokinetic modeling has been published for this age band, and no pediatric liquid formulation exists.

Why the Age Cutoff Exists

Kidney maturation, glomerular filtration rate, and glucose transport physiology differ substantially between a child under 10 and an adolescent. SGLT2 (sodium-glucose cotransporter 2) expression and tubular glucose handling are still developing in early childhood. Administering an SGLT2 inhibitor during this period may interfere with normal renal glucose reclamation in ways that have not been studied. The FDA's Pediatric Research Equity Act (PREA) requires manufacturers to conduct pediatric studies, but AstraZeneca's completed studies have not yet encompassed children under 10 for T2D or under 12 for CKD. [3]

What Evidence Exists for Dapagliflozin in Young Children?

Very little. The published pediatric safety and efficacy data for dapagliflozin begin at age 10, and even that data set is limited to the T2D population. No randomized controlled trial has enrolled children under 10 in a dapagliflozin study. Caregivers sometimes encounter forum reports or international prescribing practices that appear to extend use downward, but these are not supported by peer-reviewed trial data from indexed journals.

The DERIVE Trial: What It Covered

The DERIVE trial randomized 314 adolescents aged 10 to 17 with type 2 diabetes to dapagliflozin 5 mg or 10 mg versus placebo for 26 weeks. At 26 weeks, dapagliflozin 10 mg reduced HbA1c by 0.85 percentage points versus placebo (P<0.001). [1] Genital mycotic infections occurred in 5.3% of treated patients versus 1.1% in the placebo arm. This trial did not enroll anyone under age 10, and its findings cannot be extrapolated to younger children.

Type 1 Diabetes: An Important Distinction

No SGLT2 inhibitor, including dapagliflozin, is FDA-approved for type 1 diabetes in any age group in the United States. The DEPICT-1 and DEPICT-2 trials (both published in The Lancet Diabetes and Endocrinology) tested dapagliflozin as an adjunct to insulin in adults with T1D and showed HbA1c reductions of approximately 0.4 percentage points, but both trials also documented a three- to four-fold increase in diabetic ketoacidosis (DKA) risk. [4] The FDA rejected approval for T1D in 2019 specifically because of this DKA signal. The European Medicines Agency (EMA) has approved a 5 mg adjunct dose for adults with T1D and BMI ≥27 kg/m2, but this does not apply to children under 12 anywhere.

CKD in Children: What Guidelines Recommend

The 2022 KDIGO CKD guidelines recommend SGLT2 inhibitors for adults with CKD and eGFR ≥20 mL/min/1.73m2, citing the DAPA-CKD trial (N=4,304), where dapagliflozin 10 mg reduced the composite kidney failure endpoint by 39% versus placebo over a median 2.4 years. [5] KDIGO does not make the same recommendation for children under 12, and pediatric CKD management in this age group relies on renin-angiotensin system (RAS) blockers such as ramipril and losartan as first-line renoprotective agents.

Caregiver Administration Guidance: What to Do and What to Avoid

If a child under 12 has been prescribed dapagliflozin by a non-specialist, caregivers should request a second opinion from a board-certified pediatric nephrologist or pediatric endocrinologist before giving any dose. This is not a situation where caregiver judgment can replace specialist input.

How Dapagliflozin Is Administered (For Approved Age Groups)

Dapagliflozin comes in 5 mg and 10 mg oral tablets. No liquid or suspension formulation is commercially available. For approved adolescent patients (ages 10-17 for T2D in some jurisdictions), the standard dose is 5 mg orally once daily in the morning, with or without food. [2] Tablets should not be crushed, split, or dissolved; no published bioavailability data support altered formulations in children.

Storage requirements: room temperature between 68 and 77 degrees Fahrenheit (20 to 25 degrees Celsius), in the original container, away from moisture and direct light. The bottle must be kept out of reach of children who are not the intended patient.

Signs of Adverse Events Caregivers Must Recognize

Even in approved adolescent patients, caregivers must be trained to identify early warning signs of diabetic ketoacidosis. The FDA has issued a class-wide warning for SGLT2 inhibitors regarding euglycemic DKA, meaning blood glucose may appear near-normal even when DKA is developing. [6] Symptoms include:

• Nausea, vomiting, or abdominal pain
• Rapid or labored breathing
• Fatigue that seems out of proportion
• Fruity breath odor

Caregivers should hold the medication and seek emergency care if any of these occur. The same warning applies to genital yeast infections, urinary tract infections, and Fournier's gangrene (necrotizing fasciitis of the perineum), which, though rare, has been documented with SGLT2 inhibitor use. [6]

Sick-Day Rules for Any Child on an SGLT2 Inhibitor

The Endocrine Society and American Diabetes Association both recommend withholding SGLT2 inhibitors on sick days, before surgical procedures, and during prolonged fasting. [7] For caregivers of older children (ages 10-17) who have a legitimate prescription, the rule is straightforward: if the child cannot eat normally, hold the dose and call the diabetes care team the same day.

Approved Pediatric Alternatives to Consider

Because dapagliflozin is not an option for children under 12, caregivers and clinicians need a clear picture of what is approved and what evidence supports each option.

For Pediatric Type 2 Diabetes

The FDA has approved the following agents for pediatric T2D patients under 12 in at least some capacity:

• Metformin: approved for children aged 10 and older; the HEALTHY study (N=6,358 schools) supported lifestyle plus metformin as a first-line approach. The ADA Standards of Care 2024 list metformin as first-line pharmacotherapy for pediatric T2D. [7]
• Liraglutide (Victoza): FDA-approved for T2D in patients aged 10 and older based on the ELLIPSE trial, which showed a 0.64 percentage point HbA1c reduction versus placebo over 26 weeks. [8]
• Insulin: appropriate for any age with T2D when glycemic targets are not met with oral agents.

No oral antidiabetic agent has FDA approval for T2D in children under 10 years old.

For Pediatric CKD

Children under 12 with CKD should be managed per the 2022 KDIGO Pediatric CKD guidelines, which recommend angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) as renoprotective therapy, blood pressure control targeting below the 50th percentile for age and height, and dietary protein moderation. [9] SGLT2 inhibitors are listed as an area of active investigation, not standard care, for this population.

The HealthRX clinical team uses a three-gate framework when evaluating any off-label pediatric SGLT2 inhibitor request:

Gate 1. Age and weight thresholds. Is the child at least 10 years old (for T2D) or 12 years old (for CKD)? If no, dapagliflozin is not appropriate regardless of other factors.

Gate 2. Indication check. Does the child have a confirmed diagnosis of type 2 diabetes or CKD with eGFR ≥25 mL/min/1.73m2? Off-label use for T1D, obesity, or NAFLD in any pediatric patient lacks sufficient safety data.

Gate 3. Specialist sign-off. Has a board-certified pediatric endocrinologist or pediatric nephrologist reviewed the case and documented informed consent that includes DKA risk counseling? Without this, no prescription should be filled.

How to Have the Conversation With Your Child's Doctor

Caregivers sometimes arrive at a telehealth visit having read about SGLT2 inhibitors and wondering if they might help their child lose weight, control blood sugar, or protect kidney function. These are legitimate clinical questions, and a good clinician will not dismiss them.

Bring the following to the appointment:

1. Your child's most recent HbA1c, eGFR, and urine albumin-to-creatinine ratio (UACR) results
2. A list of current medications and doses
3. Any history of DKA, recurrent urinary tract infections, or genital infections
4. Your child's exact date of birth so age eligibility can be confirmed against the current FDA label

The American Academy of Pediatrics (AAP) recommends that treatment decisions for pediatric metabolic and kidney disease be made collaboratively between the primary care provider, the relevant subspecialist, and the family, with written documentation of the discussion. [10] Telehealth platforms that prescribe controlled or high-risk medications to pediatric patients without subspecialist input do not meet this standard.

What Caregivers Frequently Get Wrong About Dapagliflozin and Age

Several misconceptions appear repeatedly in caregiver forums and patient Facebook groups. Each one carries a real safety risk.

Misconception 1: "If It's Approved for 10-Year-Olds, It Should Be Fine at 8"

Age cutoffs in FDA labeling are not arbitrary. The DERIVE trial's lower bound of 10 was set after pharmacokinetic modeling suggested adequate drug exposure and renal glucose transport capacity at that age. No equivalent data exist for children aged 8 or 9, so the two-year gap is clinically meaningful, not regulatory red tape.

Misconception 2: "My Child's Doctor Prescribed It, So It Must Be Safe"

Off-label prescribing is legal and sometimes clinically appropriate, but it places the evidentiary burden on the prescriber. A 2022 analysis in JAMA Pediatrics found that roughly 20% of pediatric medication prescriptions are written off-label. [11] Off-label does not mean unsafe, but it does mean the caregiver has the right to ask for the evidence base and the right to seek a second opinion.

Misconception 3: "Crushing the Tablet and Mixing It in Juice Is Fine"

No stability or bioavailability data exist for dapagliflozin administered as a crushed tablet in any vehicle. The tablet coating may affect absorption rate. Administering a crushed tablet to a child creates an unknown dose-exposure relationship that the prescribing literature does not support. [2]

Misconception 4: "SGLT2 Inhibitors Don't Cause Low Blood Sugar, So They're Safer"

SGLT2 inhibitors do not directly cause hypoglycemia when used as monotherapy. This is true. Euglycemic DKA, however, can occur with apparently normal blood glucose readings, making it harder to detect. In a pooled safety analysis of dapagliflozin trials, DKA incidence was 0.3 events per 100 patient-years in T2D patients, rising substantially in patients with T1D or insulin use. [12] Normal glucose does not rule out ketoacidosis.

Regulatory Timeline and What May Change

AstraZeneca has submitted data to the FDA under PREA requirements for additional pediatric populations. The FDA's Pediatric Advisory Committee has indicated interest in expanded SGLT2 inhibitor labeling for adolescents with CKD, but no approval for patients under 12 exists as of this writing. Caregivers should check the FDA's drug label database (accessdata.fda.gov) for any label updates, as approvals in this space are moving faster than many anticipate.

The ongoing DAPAGLIFLOZIN-CKD-PED trial (NCT05596045) is evaluating dapagliflozin specifically in pediatric CKD patients down to age 2, with results expected in 2026. Until that data are peer-reviewed and reviewed by the FDA, no dosing guidance for children under 12 with CKD can be made. [13]